Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection.

Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J Virol (2006) 2.50

Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol (2009) 2.16

The Antibody Response against HIV-1. Cold Spring Harb Perspect Med (2012) 1.65

Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques. J Virol (1999) 1.60

Intrinsic susceptibility of rhesus macaque peripheral CD4(+) T cells to simian immunodeficiency virus in vitro is predictive of in vivo viral replication. J Virol (2000) 1.47

Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope. J Virol (1999) 1.38

Microarray profiling of antibody responses against simian-human immunodeficiency virus: postchallenge convergence of reactivities independent of host histocompatibility type and vaccine regimen. J Virol (2003) 1.04

Unique pattern of convergent envelope evolution in simian immunodeficiency virus-infected rapid progressor macaques: association with CD4-independent usage of CCR5. J Virol (2003) 1.03

Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections. J Virol (2007) 1.03

Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees. J Virol (2000) 0.81

Comparison of the specificities of IgG, IgG-subclass, IgA and IgM reactivities in African and European HIV-infected individuals with an HIV-1 clade C proteome-based array. PLoS One (2015) 0.79

Pandemic HIV-1 Vpu overcomes intrinsic herd immunity mediated by tetherin. Sci Rep (2015) 0.78

Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170). AIDS (2012) 0.77

Use of principal components analysis and protein microarray to explore the association of HIV-1-specific IgG responses with disease progression. AIDS Res Hum Retroviruses (2013) 0.76

Variations in the Biological Functions of HIV-1 Clade C Envelope in a SHIV-Infected Rhesus Macaque during Disease Progression. PLoS One (2013) 0.75

The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study. BMC Infect Dis (2017) 0.75

Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol (1999) 18.82

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med (2000) 11.90

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol (1999) 9.11

Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. Science (1986) 7.81

Human skin Langerhans cells are targets of dengue virus infection. Nat Med (2000) 5.74

HIV infection in homosexual and bisexual men 18 to 29 years of age: the San Francisco Young Men's Health Study. Am J Public Health (1994) 5.18

Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J Virol (1994) 4.35

A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research. N Engl J Med (1991) 4.23

ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol (2002) 4.11

Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbiol (2000) 3.83

Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science (1998) 3.60

Molecular cloning and complete nucleotide sequence of the attenuated rabies virus SAD B19. Virology (1990) 3.46

Detection of diverse HIV-1 genetic subtypes in the USA. Lancet (1995) 3.41

The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med (1997) 3.36

Viral burden and HIV disease. Nature (1993) 3.18

HIV-1 suppression during acute scrub-typhus infection. Lancet (2000) 3.08

The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nat Med (1997) 3.05

Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci U S A (1991) 2.85

Human immunodeficiency virus infections among civilian applicants for United States military service, October 1985 to March 1986. Demographic factors associated with seropositivity. N Engl J Med (1987) 2.81

Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants. Virology (1998) 2.76

Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group. Lancet (1999) 2.74

Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. J Virol (1997) 2.72

HTLV-III in symptom-free seronegative persons. Lancet (1984) 2.71

Catheter-associated sepsis caused by Ochrobactrum anthropi: report of a case and review of related nonfermentative bacteria. Clin Infect Dis (1992) 2.70

Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes. J Clin Microbiol (1999) 2.68

Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med (1987) 2.59

Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J Virol (2006) 2.57

Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms. J Clin Microbiol (1999) 2.51

Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. AIDS Res Hum Retroviruses (1994) 2.47

The Walter Reed staging classification for HTLV-III/LAV infection. N Engl J Med (1986) 2.44

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol (2001) 2.43

Nuclear localization of a double-stranded RNA-binding protein encoded by the vaccinia virus E3L gene. Virology (1993) 2.40

Recovery of virtually full-length HIV-1 provirus of diverse subtypes from primary virus cultures using the polymerase chain reaction. Virology (1995) 2.38

CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J Virol (1998) 2.38

Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS (2000) 2.32

Type-restricted neutralization of molecular clones of human immunodeficiency virus. Science (1988) 2.31

Measurement of the false positive rate in a screening program for human immunodeficiency virus infections. N Engl J Med (1988) 2.22

Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol (1985) 2.20

Rabies virus glycoprotein. II. Biological and serological characterization. Infect Immun (1977) 2.14

Cytomegalovirus DNA detection in sera from patients with active cytomegalovirus infections. J Clin Microbiol (1992) 2.14

Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: evidence for viral replication in all stages of HIV disease. J Virol (1992) 2.11

HIV-1 entry inhibitors: evading the issue. Nat Med (1999) 2.08

False-positive Western blot tests for antibodies to HTLV-III. JAMA (1986) 2.07

Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol (1998) 2.06

Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med (2001) 2.05

Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders. N Engl J Med (1986) 2.03

A unified hypothesis for three cardinal features of HIV immunology. J Acquir Immune Defic Syndr (1991) 2.03

Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol (1987) 1.99

Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients. AIDS (1996) 1.98

HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet (1997) 1.95

Use of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 to assess the performance of viral RNA quantitation tests. J Clin Microbiol (2000) 1.95

Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity. J Immunol (1997) 1.89

Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J Virol (1997) 1.84

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet (1998) 1.80

An interchangeable ELISA for cytomegalovirus antigen and antibody. J Virol Methods (1981) 1.80

Virus-specific antibody activity of different subclasses of immunoglobulins G and A in cytomegalovirus infections. Infect Immun (1983) 1.78

Long-term human immunodeficiency virus infection in asymptomatic homosexual and bisexual men with normal CD4+ lymphocyte counts: immunologic and virologic characteristics. J Infect Dis (1991) 1.77

Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc Natl Acad Sci U S A (1992) 1.77

Frequent transmission of HTLV-III among spouses of patients with AIDS-related complex and AIDS. JAMA (1985) 1.76

Rapid "tea-bag" peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins. Immunol Lett (1991) 1.73

Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res Hum Retroviruses (1995) 1.72

Highly stable expression of a foreign gene from rabies virus vectors. Proc Natl Acad Sci U S A (1996) 1.72

Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J Virol (1997) 1.72

Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120. AIDS (1990) 1.71

Mechanisms of B cell activation in patients with acquired immunodeficiency syndrome and related disorders. Contribution of antibody-producing B cells, of Epstein-Barr virus-infected B cells, and of immunoglobulin production induced by human T cell lymphotropic virus, type III/lymphadenopathy-associated virus. J Clin Invest (1986) 1.70

Allelic forms of rat kappa chain genes: evidence for strong selection at the level of nucleotide sequence. Proc Natl Acad Sci U S A (1981) 1.70

Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. J Virol (1998) 1.69

Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet (1993) 1.68

Human immunodeficiency virus infections in teenagers. Seroprevalence among applicants for US military service. The Walter Reed Retrovirus Research Group. JAMA (1990) 1.67

Pyogenic infections due to Ochrobactrum anthropi. Clin Infect Dis (1996) 1.66

Shorter survival of SDF1-3'A/3'A homozygotes linked to CD4+ T cell decrease in advanced human immunodeficiency virus type 1 infection. J Infect Dis (2000) 1.66

A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine (2010) 1.66

Heterosexually acquired HTLV-III/LAV disease (AIDS-related complex and AIDS). Epidemiologic evidence for female-to-male transmission. JAMA (1985) 1.65

An L (polymerase)-deficient rabies virus defective interfering particle RNA is replicated and transcribed by heterologous helper virus L proteins. Virology (1991) 1.63

TAP (transporter associated with antigen processing)-independent presentation of endogenously synthesized peptides is enhanced by endoplasmic reticulum insertion sequences located at the amino- but not carboxyl-terminus of the peptide. J Immunol (1994) 1.63

Primary isolation and serial passage of hepatitis A virus strains in primate cell cultures. J Clin Microbiol (1984) 1.61

Human immunodeficiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics. J Med Virol (1989) 1.61

Chronic vaginal candidiasis in women with human immunodeficiency virus infection. JAMA (1987) 1.59

Dual infection with human immunodeficiency virus type 1 of distinct envelope subtypes in humans. J Infect Dis (1995) 1.58

Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. J Virol (1996) 1.57

Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr (1994) 1.57

Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein. J Acquir Immune Defic Syndr (1992) 1.57